If you have been reading about pituitary axis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-07. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Café de olla (lit. 'pot coffee') is a traditional Mexican coffee beverage. To prepare café de olla, it is essential to use a traditional earthen clay pot, as this gives a special flavor to the coffee. This type of coffee is principally consumed in cold climates and in rural areas. In Mexico, a basic café de olla is made with ground coffee, cinnamon and piloncillo. Optional ingredients include orange peel, anise and cloves.
Because genome-wide data still separate the lineages, they remain distinct species even though their history cannot be depicted by a simple bifurcating tree. Keuler and colleagues recommend routine hybridisation tests (e.g., gene-tree comparison, HybridDetective) in intensive delimitation projects. Overall, such studies highlight how cryptic and dynamic lichen species can be, and they continue to drive up recognized species numbers.
The tumor-suppressor protein p53 accumulates when DNA is damaged due to a chain of biochemical factors. Part of this pathway includes alpha-interferon and beta-interferon, which induce transcription of the p53 gene, resulting in the increase of p53 protein level and enhancement of cancer cell-apoptosis. p53 prevents the cell from replicating by stopping the cell cycle at G1, or interphase, to give the cell time to repair; however, it will induce apoptosis if damage is extensive and repair efforts fail. Any disruption to the regulation of the p53 or interferon genes will result in impaired apoptosis and the possible formation of tumors.
Several phase 1 clinical trials have been performed by experts in the field of adoptive immunotherapy of cancer. Hans Klingemann and Sally Arai completed a US trial at Rush University Medical Center (Chicago) in renal cell cancer and melanoma patients in 2008, and Torsten Tonn, MD and Oliver Ottmann, MD completed the European trial at the University of Frankfurt in patients with various solid and hematological malignancies in 2013. Armand Keating at Princess Margaret Hospital in Toronto conducted a trial in which NK-92 cells were given to patients who had relapsed after autologous bone marrow transplants for leukemia or lymphoma. In all clinical trials so far, NK-92 cells were administered as a simple intravenous infusion, dosed two or three times per treatment course, and given in the outpatient setting. Of the 39 patients enrolled across the three studies, 2 serious (grade 3–4) side-effects occurred during or after the infusion of NK-92 cells, the side effects disappeared afterward. The doses given to patients ranged from 1 × 108 cells/m2 to 1 × 1010 cells/m2 per infusion. Patients received between two and three infusions over a period of less than a week. About one-third of the treated patients had clinically meaningful responses with some of them fully recovering.
Sources: en.wikipedia.org
Another interesting scaffold used as a platform for supramolecularly assembled ArMs are multidrug resistance regulators (MDRs), particularly a PadR family of proteins without native catalytic activity, whose function in nature is the recognition of foreign agents and to activate subsequent cellular response. Among them, Lactococcal multidrug resistance regulator (LmrR) was mainly used to create ArMs, using different strategies, including the supramolecular one. Namely, Roelfes et al. incorporated Cu(II) phenanthroline complex in the hydrophobic pocket of LmrR and performed Friedel-Crafts reaction enantioselectively; and Fe heme complex which catalyzed cyclopropanation enantioselectively.
Burger King's menu has expanded from a basic offering of burgers, french fries, sodas, and milkshakes to a larger and more diverse set of products. In 1957, the "Whopper" became the first major addition to the menu, and it has since become Burger King's signature product. Conversely, Burger King has introduced many products that have failed to catch hold in the market. Some of these failures in the United States have seen success in foreign markets, where Burger King has also tailored its menu for regional tastes. From 2002 to 2010, Burger King targeted the 18–34 male demographic with larger products that often carried correspondingly large amounts of unhealthy fats and trans-fats. This tactic would eventually damage the company's financial underpinnings and cast a negative pall on its earnings. Beginning in 2011, the company began to move away from its previous male-oriented menu and introduce new menu items, product reformulations, and packaging, as part of its current owner 3G Capital's restructuring plans of the company. As of December 31, 2018, Burger King reported having 17,796 outlets in 100 countries. Of these, nearly half are located in the United States, and 99.7% are privately owned and operated, with its new owners moving to an almost entirely franchised model in 2013. Burger King has historically used several variations of franchising to expand its operations.
It has also been reported in people with noninflammatory musculoskeletal disorders. The prevalence of fibromyalgia in gastrointestinal disease has been described mostly for celiac disease and irritable bowel syndrome. IBS and fibromyalgia may share similar pathogenic mechanisms involving mast cell abnormalities, inflammatory biomarkers, hormones, and neurotransmitters such as serotonin. Dysbiosis alters serotonin transmission, leading to autonomic nervous system hyperstimulation. Other conditions that are associated with fibromyalgia include obesity, connective tissue disease, cardiovascular autonomic abnormalities, obstructive sleep apnea (hypopnea syndrome), restless legs syndrome, and overactive bladder.
=== Multimodal therapy === Despite the extensive investigation into single therapeutic targets for cachexia, the most effective treatments use multi-targeted therapies. In Europe, a combination of non-drug approaches including physical training, nutritional counseling, and psychotherapeutic intervention are used in belief this approach may be more effective than monotherapy. Administration of anti-inflammatory drugs showed efficacy and safety in the treatment of people with advanced cancer cachexia.
1,4-Butanediol, also called butane-1,4-diol (other names include 1,4-B, BD, dose, BDO, and 1,4-BD), is a primary alcohol and an organic compound with the formula HOCH2CH2CH2CH2OH. It is a colorless viscous liquid first synthesized in 1890 via acidic hydrolysis of N,N'-dinitro-1,4-butanediamine by Dutch chemist Pieter Johannes Dekkers, who called it "tetramethylene glycol".
Sources: en.wikipedia.org
Color-flow Doppler ultrasound measures the severity of peripheral vascular disease and is used by cardiologists for dynamic evaluation of the heart, heart valves, and major vessels. Stenosis, for example, of the carotid arteries may be a warning sign for an impending stroke. A clot, embedded deep in one of the inner veins of the legs, can be found via ultrasound before it dislodges and travels to the lungs, resulting in a potentially fatal pulmonary embolism. Ultrasound is useful as a guide to performing biopsies to minimize damage to surrounding tissues and in drainages such as thoracentesis. Small, portable ultrasound devices now replace peritoneal lavage in trauma wards by non-invasively assessing for the presence of internal bleeding and any internal organ damage. Extensive internal bleeding or injury to the major organs may require surgery and repair.
Sibabrata Mukhopadhyay, Mumu Chakraborty, Arun Bandyopadhyay, Dipak Kar, Tanima Banerjee, Aditya Konar, Debaprasad Jana, Siddhartha Roy, Santu Bandyopadhyay, Balram Ghosh, Mabalirajan Ulaganathan, Rakesh Johri, Subhash Sharma, Gurdarshan Singh, Bholanath Paul, Vasanta Madhava Sharma Gangavaram, Jhillu Singh Yadav, Radha Krishna Palakodety (August 2013). "Method for treatment of bronchial asthma (Patent US8519154B2)". {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: multiple names: authors list (link) Sujoy K Das Gupta, Abhik Saha, Archana Sharma, Siddhartha Roy, Bhabatarak Bhattacharya (January 2012). "Peptide antagonists for inhibiting heat shock protein (Hsp 16.3) of Mycobacterium tuberculosis (Patent 7569537)". Retrieved 15 October 2016.{{cite web}}: CS1 maint: multiple names: authors list (link) S. Bandyopadhay, B. Ghosh, Parasuraman Jaisankar, Bikas C Pal, Siddhartha Roy, Nath Paul, Arjun Ram, U. Mabalirajan, Nahid Ali, Arun Bandyopadhyay, Aditya Konar, J. B. Chakraborty, I. C. Mukherjee, Jaydeep Chaudhuri, Sanjit Kumar Mahato, A. Manna, Roma Sinha, Pradyot Bhattacharya, J. Vinayagam, Sudeshna Chowdhury (January 2012). "Substituted catechols as inhibitors of IL-4 and IL-5 for the treatment of bronchial asthma (WO Patent 2,012,140,574)". doi:10.13140/RG.2.1.2784.6488. Retrieved 15 October 2016. {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: multiple names: authors list (link) 1st S. Bandyopadhay, B. Ghosh, Parasuraman Jaisankar, Bikas C Pal, Siddhartha Roy, Nath Paul, Arjun Ram, U.
The increasing aggressiveness of Hitler prompted the Czechoslovak military to start to build extensive border fortifications in 1936 to defend the troubled border region. Immediately after the Anschluss of Austria into the German Reich in March 1938, Hitler made himself the advocate of ethnic Germans living in Czechoslovakia, which triggered the Sudeten Crisis. The following month, Sudeten Nazis, led by Konrad Henlein, agitated for autonomy. On 24 April 1938, the SdP proclaimed the Karlsbader Programm, which demanded in eight points the complete equality between the Sudeten Germans and the Czech people. The government accepted those claims on 30 June 1938. In August, British Prime Minister Neville Chamberlain sent Lord Runciman on a mission to Czechoslovakia to see if he could obtain a settlement between the Czechoslovak government and the Germans in the Sudetenland. Runciman's first day included meetings with President Beneš and Prime Minister Milan Hodža as well as a direct meeting with the Sudeten Germans from Henlein's SdP. On the next day, he met with Dr and Mme Beneš and later met non-Nazi Germans in his hotel. A full account of his report, including summaries of the conclusions of his meetings with the various parties, which he made in person to the Cabinet on his return to the United Kingdom, is found in the Document CC 39(38). Lord Runciman expressed sadness that he could not bring about agreement with the various parties, but he agreed with Lord Halifax that the time that had been gained was important.
April 8: Decree protecting wives of political emigrants, but not husbands of female emigrants. August 31: Decree adjusting penalties for pregnant women sentenced to the pillory. September 20: Law on civil status registration and divorce, establishing near equality between spouses. Minimum marriage age set at 13 for girls and 15 for boys. 1793
== Structures involved in clinical attachment loss == Clinical attachment loss refers to the apical migration and destruction of the tissues that secure the tooth within the periodontium. This process involves the coordinated breakdown of epithelial, connective tissue, and osseous components that collectively form the periodontal attachment apparatus.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.